Venezuela
artista independiente
Responsible for formulating the company's business plans and goals and coordinating work among various departments. Develop your own work goals and work plans, and conscientiously complete your respective tasks in accordance with the company's requirements Skill introduction: From 2015 to 2021, Sanofi Group released a number of innovative drugs, providing patients with new treatment options. 2015 Tofacitinib: A JAK inhibitor used to treat conditions such as rheumatoid arthritis, ankylosing spondylitis, and Crohn's disease. Ocrelizumab: A B-cell selective apoptotic agent used to treat multiple sclerosis. 2016 Adalimumab: A TNF-alpha inhibitor used to treat conditions such as rheumatoid arthritis, ankylosing spondylitis, and Crohn's disease. Eculizumab: A C5 complement inhibitor used to treat hereditary angioedema. 2017 Alogliptin: A DPP-4 inhibitor used to treat diabetes. Voglitazone: A PPARγ agonist used to treat diabetes. 2018 Olaparib: A PARP inhibitor used to treat BRCA-mutated ovarian cancer, breast cancer and other diseases. Dacomitinib (Dapagliflozin): An SGLT-2 inhibitor used to treat diabetes. 2019 Alogliptin/Voglitazone: A DPP-4 inhibitor/PPARγ agonist combination used to treat diabetes. Dapagliflozin/Empagliflozin: A combination SGLT-2 inhibitor/SGLT-1 inhibitor used to treat diabetes. 2020 Sorafenib: A multi-target tyrosine kinase inhibitor used to treat hepatocellular carcinoma, renal cell carcinoma and other diseases. Cagliptin: A DPP-4 inhibitor used to treat diabetes. 2021 Setonacept: An IL-23p19 inhibitor used to treat conditions such as Crohn's disease and ankylosing spondylitis. Alogliptin/Cagliptin: A combination of DPP-4 inhibitors used to treat diabetes. These drugs have shown good efficacy and safety in clinical trials, providing patients with new treatment options. Sanofi Group will continue to be committed to developing innovative drugs to bring greater health benefits to patients.